drugset / Trial / NCT05980806
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
Timeline
- Start
- 2024-04-22
- Primary completion
- 2027-06
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 40 mg | Oral |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Background | Momelotinib | Small molecule | — | — |
| Background | Pacritinib | Small molecule | 200 mg | — |
| Background | Ruxolitinib | Small molecule | — | — |